Results 171 to 180 of about 1,877,035 (363)

Cell surface interactome analysis identifies TSPAN4 as a negative regulator of PD‐L1 in melanoma

Molecular Oncology, EarlyView.
Using cell surface proximity biotinylation, we identified tetraspanin TSPAN4 within the PD‐L1 interactome of melanoma cells. TSPAN4 negatively regulates PD‐L1 expression and lateral mobility by limiting its interaction with CMTM6 and promoting PD‐L1 degradation.
Guus A. Franken, Andrea Abel Gutierrez, Imke van Rossum, Cornelia G. Spruijt, Michiel Vermeulen, Guido van Mierlo, Blanca Scheijen, Annemiek B. van Spriel   +7 more
wiley   +1 more source

CCR5AS lncRNA variation differentially regulates CCR5, influencing HIV disease outcome. [PDF]

, 2019
Multiple genome-wide studies have identified associations between outcome of human immunodeficiency virus (HIV) infection and polymorphisms in and around the gene encoding the HIV co-receptor CCR5, but the functional basis for the strongest of these ...
Anderson, Stephen K, Carrington, Mary, Chowdhury, Fatema Z, Deeks, Steven G, Ewy, Rodger, Gatanaga, Hiroyuki, Goedert, James J, Haas, David W, Hoots, W Keith, Kirk, Gregory D, Kulkarni, Smita, Kulkarni, Viraj, Le Gall, Sylvie, Lied, Alexandra, Lin, Zhansong, Margolick, Joseph, Martin, Maureen P, McLaren, Paul J, Michael, Nelson, Naranbhai, Vivek, Nguyen, Hoang, Oka, Shinichi, Rucevic, Marijana, Singh, Sukhvinder, Takiguchi, Masafumi, Thio, Chloe L, Viard, Mathias, Walker, Bruce, Walker-Sperling, Victoria, Yu, Xu G, Zou, Chengcheng   +30 more
core  

An Investigation of the 16‐S RNA Binding Sites of Ribosomal Proteins S4, S8, S15 and S20 from Escherichia coli [PDF]

, 1975
Ernst Ungewickell, Roger A. Garrett, Chantal Ehresmann, Patrick Stiegler, Peter Fellner   +4 more
openalex   +1 more source

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

Molecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor   +10 more
wiley   +1 more source

Alleviation of Human Papillomavirus E2-Mediated Transcriptional Repression via Formation of a TATA Binding Protein (or TFIID)-TFIIB-RNA Polymerase II-TFIIF Preinitiation Complex

, 2000
Samuel Y. Hou, Shwu-Yuan Wu, Tianyuan Zhou, Mary C. Thomas, Cheng-Ming Chiang   +4 more
openalex   +2 more sources

The RNA Binding Protein TLS Is Translocated to Dendritic Spines by mGluR5 Activation and Regulates Spine Morphology [PDF]

, 2005
Ritsuko Fujii, Shigeo Okabe, Tomoe Urushido, Kiyoshi Inoue, Atsushi Yoshimura, Taro Tachibana, Toru Nishikawa, Geoffrey G. Hicks, Toru Takumi   +8 more
openalex   +1 more source

Identification of RNA Binding Protein Signature to Predict Overall Survival for Bladder Cancer

, 2021
Danxia Li, Wenkai Han, Kai Che, Haitao Niu   +3 more
openalex   +1 more source

Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition

Molecular Oncology, EarlyView.
We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li, Shuichi Tatarano, Hirofumi Yoshino, Saeki Saito, Mitsuhiko Tominaga, Junya Arima, Ikumi Fukuda, Takashi Sakaguchi, Ryosuke Matsushita, Yasutoshi Yamada, Hideki Enokida   +10 more
wiley   +1 more source

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source

Exploration of RNA-binding proteins identified RPS27 as a potential regulator associated with Kaposi’s sarcoma development

BMC Cancer
Background Kaposi's sarcoma (KS) is a locally aggressive, multicentric tumor. RNA-binding proteins (RBPs) are pivotal for post-transcriptional regulation in various tumors.
Jingzhan Zhang, Peng Wang, Tingting Li, Dong Luo, Yuanyuan Qu, Yuan Ding, Xiaojing Kang   +6 more
doaj   +1 more source